Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17.9	19.76	23.63	17.11	38.99	18.27
Short-Term Investments	15.5	15.07	20.93	5.07	-	20.28
Cash & Short-Term Investments	33.4	34.83	44.56	22.18	38.99	38.55
Cash Growth	-25.83%	-21.84%	100.90%	-43.11%	1.14%	116.64%
Accounts Receivable	9.44	2.91	5.27	4.59	3.44	2
Other Receivables	-	0.49	0.48	0.36	0.31	0.77
Receivables	9.44	3.4	5.75	4.95	3.75	2.77
Inventory	21.13	21.24	19.05	16.8	17.95	13.08
Prepaid Expenses	-	0.5	0.44	0.77	0.91	0.84
Other Current Assets	1.51	0.11	0.13	0.17	0.07	0.48
Total Current Assets	65.49	60.08	69.93	44.88	61.67	55.72
Property, Plant & Equipment	9.74	10.02	10.88	9.64	9.92	10.41
Long-Term Deferred Tax Assets	2.74	2.86	3.09	-	-	-
Other Long-Term Assets	0.52	0.46	0.53	1.27	2.08	1.8
Total Assets	78.49	73.42	84.43	55.79	73.67	67.93
Accounts Payable	6.69	4.53	4.32	5.86	6.99	7.22
Accrued Expenses	11.81	13.8	13.2	11.6	16.34	13.61
Current Portion of Long-Term Debt	-	-	20.25	-	-	58.51
Current Portion of Leases	1.47	1.5	1.41	1.12	1.21	1.42
Current Income Taxes Payable	3.74	3.48	2.88	0.53	-	-
Current Unearned Revenue	-	-	-	13.18	8.55	5.39
Other Current Liabilities	0.38	2.31	3.48	0.14	0.1	0.32
Total Current Liabilities	24.09	25.62	45.53	32.43	33.18	86.47
Long-Term Debt	-	-	-	28.19	27.89	-
Long-Term Leases	3.88	4.03	4.62	4.17	4.38	4.47
Long-Term Unearned Revenue	-	-	-	-	11.79	1.72
Other Long-Term Liabilities	-	-	-	-	-	0.05
Total Liabilities	28.58	30.21	50.87	66.43	79.7	94.97
Common Stock	0.08	0.08	0.07	0.05	0.05	0.04
Additional Paid-In Capital	431.67	421.53	415.05	379.17	368.85	320.28
Retained Earnings	-381.85	-378.39	-381.55	-389.86	-374.93	-347.35
Shareholders' Equity	49.9	43.21	33.57	-10.64	-6.04	-27.04
Total Liabilities & Equity	78.49	73.42	84.43	55.79	73.67	67.93
Total Debt	5.35	5.53	26.28	33.47	33.47	64.4
Net Cash (Debt)	28.05	29.3	18.28	-11.29	5.52	-25.86
Net Cash Growth	48.59%	60.31%	-	-	-	-
Net Cash Per Share	0.34	0.36	0.22	-0.23	0.12	-0.89
Filing Date Shares Outstanding	79.73	78.03	73.05	57.35	46.32	45.38
Total Common Shares Outstanding	79.73	75.85	72.95	53.79	45.56	34.77
Working Capital	41.39	34.46	24.4	12.45	28.49	-30.75
Book Value Per Share	0.63	0.57	0.46	-0.20	-0.13	-0.78
Tangible Book Value	49.9	43.21	33.57	-10.64	-6.04	-27.04
Tangible Book Value Per Share	0.63	0.57	0.46	-0.20	-0.13	-0.78
Machinery	-	22.42	22.02	21.32	20.96	20.11
Leasehold Improvements	-	17.91	17.64	16.92	16.76	16.66

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q